Clover Health (CLOV) Price-to-Sales Discount Challenges Skeptics as Profitability Forecast Strengthens

Clover Health Investments (CLOV) is currently unprofitable, but the company has managed to cut its losses by 25.5% per year over the past five years. Revenue is forecast to grow at 14.9% per year, outpacing the broader US market’s 10.4% growth rate. Meanwhile, earnings are expected to surge at an impressive 77.48% per year, with profitability anticipated within three years. While the share price has experienced volatility in recent months, investors are weighing the mix of swift growth and improving margins as the company moves closer to profitability.

See our full analysis for Clover Health Investments.

Now, let’s see how these results measure up against the dominant narratives for CLOV. This is where the numbers meet the story.

See what the community is saying about Clover Health Investments

Path to Positive Margins: Profitability Within Reach

• Analysts expect Clover Health’s profit margins to improve from -2.6% today to 0.4% within three years, signaling a move into profitability after years of losses.
• According to the analysts' consensus view, this margin expansion is driven in part by:
  • The company’s ongoing cost control measures, which are reducing SG&A as a percentage of revenue and supporting scalable growth.
  • Strengthening contributions from new member cohorts and improved operating leverage. Both are set to boost the bottom line as revenue grows.
• Consensus narrative notes that the upgrade to a 4-star payment year for PPO plans in 2026 will boost CMS reimbursements, directly supporting net margin expansion and reinvestment capacity.
  See if the market agrees. Read the full consensus narrative for the numbers behind this turning point.
  📊 Read the full Clover Health Investments Consensus Narrative.

Valuation Under the Microscope: Price-to-Sales Discount

• Clover Health’s Price-to-Sales Ratio of 0.9x is notably lower than its peer average of 2.2x and the broader US healthcare sector’s 1.3x. This positions the company as a value pick among industry peers.
• As the analysts' consensus view highlights:
  • This valuation discount reflects ongoing skepticism about Clover Health’s ability to reach sustainable profitability, even as its core growth metrics outpace the market.
  • The consensus analyst price target sits at 3.37, approximately 14% above the current share price of 2.97. This suggests that the market has yet to fully price in the prospects for margin and revenue expansion over the next three years.

Risks: Volatility and Reliance on Medicare

• Bears argue that continued volatility in Clover Health’s share price over the past three months, combined with heavy reliance on Medicare Advantage PPO plans, exposes the company to regulatory and reimbursement risk.
• Points from the analysts' consensus view elaborate that:
  • Adverse changes in government reimbursement rates or the 4-star bonus structure could sharply reduce revenue and net margins, threatening near-term profitability.
  • Ongoing net losses and significant competition from larger insurers reinforce questions about whether cost controls and technology advantages will be sufficient to achieve and sustain positive earnings as the company scales.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Clover Health Investments on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Have a different take on the numbers? Craft your own view in just a few minutes and shape the narrative: Do it your way

A great starting point for your Clover Health Investments research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

See What Else Is Out There

Clover Health’s persistent net losses, margin uncertainty, and reliance on regulatory-driven growth raise concerns about the company’s ability to deliver consistent financial strength.

If you prefer investments with more robust financial footing, use our solid balance sheet and fundamentals stocks screener (1974 results) to focus on companies demonstrating stronger balance sheets and resilience through changing market conditions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.